Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

ReNeuron Group Company

RENE.L
GB00BF5G6K95
A2JBKZ

Price

0.00
Today +/-
+0
Today %
+0 %
P

ReNeuron Group stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ReNeuron Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ReNeuron Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ReNeuron Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ReNeuron Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ReNeuron Group Stock Price History

DateReNeuron Group Price
8/30/20240.00 undefined
8/29/20240.00 undefined

ReNeuron Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ReNeuron Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ReNeuron Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ReNeuron Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ReNeuron Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ReNeuron Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ReNeuron Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ReNeuron Group’s growth potential.

ReNeuron Group Revenue, EBIT and net profit per share

DateReNeuron Group RevenueReNeuron Group EBITReNeuron Group Net Income
2026e1.19 M undefined-11.67 M undefined-11.23 M undefined
2025e12.23 M undefined4.89 M undefined103,935.06 undefined
2024e660,540 undefined-6.33 M undefined103,935.06 undefined
2023530,000 undefined-7.12 M undefined-5.41 M undefined
2022400,000 undefined-11.23 M undefined-9.69 M undefined
2021260,000 undefined-12.99 M undefined-11.35 M undefined
20206.07 M undefined-14.41 M undefined-11.41 M undefined
201950,000 undefined-18.3 M undefined-14.35 M undefined
201840,000 undefined-20.38 M undefined-17.62 M undefined
201750,000 undefined-18.3 M undefined-15.57 M undefined
201630,000 undefined-13.72 M undefined-11.35 M undefined
201530,000 undefined-10.39 M undefined-8.91 M undefined
201420,000 undefined-7.97 M undefined-7.07 M undefined
201320,000 undefined-7.09 M undefined-6.35 M undefined
201240,000 undefined-6.88 M undefined-6.23 M undefined
201130,000 undefined-6.67 M undefined-6.15 M undefined
201030,000 undefined-3.91 M undefined-5.85 M undefined
200990,000 undefined-4.69 M undefined-3.67 M undefined
200830,000 undefined-6.9 M undefined-6.57 M undefined
200750,000 undefined-5.96 M undefined-5.25 M undefined
200610,000 undefined-5.94 M undefined-6.37 M undefined
20050 undefined-3.34 M undefined-3.21 M undefined
20040 undefined-1.25 M undefined-810,000 undefined

ReNeuron Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0000000000000000000060000121
---------------------------91.67
---------------------------
000000000000000000000000000
-2-5-5-5-1-3-5-5-6-4-3-6-6-7-7-10-13-18-20-18-14-12-11-7-64-11
---------------------233.33----33.33-1,100.00
-2-7-4-40-3-6-5-6-3-5-6-6-6-7-8-11-15-17-14-11-11-9-500-11
-250.00-42.86---100.00-16.6720.00-50.0066.6720.00--16.6714.2937.5036.3613.33-17.65-21.43--18.18-44.44---
0.250.290.370.370.370.370.751.11.541.593.385.036.417.6914.6318.3726.832.532.532.532.6739.1356.9857.13000
---------------------------
Details

Keystats

ⓘ

Revenue and Growth

The ReNeuron Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ReNeuron Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                               
1.3214.058.85.282.110.435.137.682.790.945.539.673.983.5520.9212.3860.7153.0637.4126.3912.6322.214.557.15
0.140.100000000000000001.280.830000
0.010.870.80000.80.670.130000000003.012.770000
000000000000000000000000
3014017040035014023021028026020019034023029019051046000400230370270
1.515.169.775.682.460.576.168.563.21.25.739.864.323.7821.2112.5761.2253.5241.729.9913.0322.4314.927.42
0.581.242.211.921.631.381.211.0410.830.540.420.30.210.230.160.360.721.481.341.040.690.660.62
000000000000000050000000
0000000130140140140140140140280280100000000
0000002.991.273.423.421.271.271.271.271.271.591.5900.190.190.190.190.190.19
0000-1.71-1.61-4.4100000000000000000
000000000000000000000000
0.581.242.211.92-0.08-0.23-0.212.444.564.391.951.831.711.621.782.036.960.721.671.531.230.880.850.81
2.0816.411.987.62.380.345.95117.765.597.6811.696.035.422.9914.668.1854.2443.3731.5214.2623.3115.778.23
                                               
2.393.493.5903.593.599.361.381.541.544.386.26.237.7517.8917.8931.6531.650.320.320.320.570.570.57
018.3618.36000.375.4713.2114.3614.3621.3128.8128.8932.9746.2746.2797.797.797.797.797.89113.9113.93113.93
-2.16-6.68-10.690-1.75-4.96-10.2-4.41-8.96-12.42-18.26-24.01-29.89-35.81-42.44-51.02-61.69-76.19-61.47-74.78-84.99-95.57-104.61-109.44
0007.200000000000000000000
000000000000000000000000
0.2315.1711.267.21.84-14.6310.186.943.487.43115.234.9121.7213.1467.6653.1636.5523.2413.2218.99.895.06
0.280.680.340.510.750.270.780.40.350.490.360.860.960.491.161.061.51.825.827.262.431.720.730.32
1.570.370.260.60.280.310.540.410.390.190.220.360.440.680.881.292.23.89003.854.016.143.85
0000001010306010000005000000000
000000000000000000000000
000001.25000.050.040.010.010.01000000.030.140.170.160.150.15
1.851.050.61.111.031.831.330.820.820.780.61.231.411.172.042.354.25.715.857.46.455.897.024.32
0000000002.090.020.010000000.970.860.710.560.420.27
000000000000000000000000
01901206001000008010013015036061000000000
00.190.120.0600.010002.090.10.110.130.150.360.61000.970.860.710.560.420.27
1.851.240.721.171.031.841.330.820.822.870.71.341.541.322.42.964.25.716.828.267.166.457.444.59
2.0816.4111.988.372.870.845.96117.766.358.1312.346.776.2324.1216.171.8658.8743.3731.520.3825.3517.339.65
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ReNeuron Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ReNeuron Group's financial health and stability.

Assets

ReNeuron Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ReNeuron Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ReNeuron Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ReNeuron Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-2-7-5-5-1-3-6-5-6-4-6-6-6-7-7-10-12-18-20-17-13-13-11-6
01,0000000000000000000000000
000000000000000000000611
1-1000000000000110344-152-1
020000000020000001100100
000000000000000000000000
00000000000000000-1-4-30-6-1-1
-1-4-3-3-2-2-4-5-6-4-2-5-5-6-6-8-11-12-14-11-14-6-7-7
0-1-2000000000000000000000
0-1-20-10000000000000000023
0000-10000000000000000024
000000000000000000000000
000001100200000000000000
22100109010710062506800001700
1653429712790517616231446800
0-14533107000000-76-51231446-800
000000000000000000000000
00000052-4-144-5011-25100-7-72-5-3
-1.19-6.68-5.6-3.79-2.94-2.82-4.58-5.56-6.2-4.43-2.64-5.18-5.82-6.06-6.12-8.31-12.21-13.17-15.13-12.19-14.42-6.08-7.71-7.7
000000000000000000000000

ReNeuron Group stock margins

The ReNeuron Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ReNeuron Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ReNeuron Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ReNeuron Group's sales revenue. A higher gross margin percentage indicates that the ReNeuron Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ReNeuron Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ReNeuron Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ReNeuron Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ReNeuron Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ReNeuron Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ReNeuron Group Margin History

ReNeuron Group Gross marginReNeuron Group Profit marginReNeuron Group EBIT marginReNeuron Group Profit margin
2026e100 %-978.84 %-942.38 %
2025e100 %39.99 %0.85 %
2024e100 %-957.95 %15.73 %
2023100 %-1,343.4 %-1,020.75 %
2022100 %-2,807.5 %-2,422.5 %
2021100 %-4,996.15 %-4,365.39 %
2020100 %-237.4 %-187.97 %
2019100 %-36,600 %-28,700 %
2018100 %-50,950 %-44,050 %
2017100 %-36,600 %-31,140 %
2016100 %-45,733.33 %-37,833.33 %
2015100 %-34,633.33 %-29,700 %
2014100 %-39,850 %-35,350 %
2013100 %-35,450 %-31,750 %
2012100 %-17,200 %-15,575 %
2011100 %-22,233.33 %-20,500 %
2010100 %-13,033.33 %-19,500 %
2009100 %-5,211.11 %-4,077.78 %
2008100 %-23,000 %-21,900 %
2007100 %-11,920 %-10,500 %
2006100 %-59,400 %-63,700 %
2005100 %0 %0 %
2004100 %0 %0 %

ReNeuron Group Stock Sales Revenue, EBIT, Earnings per Share

The ReNeuron Group earnings per share therefore indicates how much revenue ReNeuron Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ReNeuron Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ReNeuron Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ReNeuron Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ReNeuron Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ReNeuron Group Revenue, EBIT and net profit per share

DateReNeuron Group Sales per ShareReNeuron Group EBIT per shareReNeuron Group Earnings per Share
2026e0.02 undefined0 undefined-0.2 undefined
2025e0.21 undefined0 undefined0 undefined
2024e0.01 undefined0 undefined0 undefined
20230.01 undefined-0.12 undefined-0.09 undefined
20220.01 undefined-0.2 undefined-0.17 undefined
20210.01 undefined-0.33 undefined-0.29 undefined
20200.19 undefined-0.44 undefined-0.35 undefined
20190 undefined-0.56 undefined-0.44 undefined
20180 undefined-0.63 undefined-0.54 undefined
20170 undefined-0.56 undefined-0.48 undefined
20160 undefined-0.51 undefined-0.42 undefined
20150 undefined-0.57 undefined-0.49 undefined
20140 undefined-0.54 undefined-0.48 undefined
20130 undefined-0.92 undefined-0.83 undefined
20120.01 undefined-1.07 undefined-0.97 undefined
20110.01 undefined-1.33 undefined-1.22 undefined
20100.01 undefined-1.16 undefined-1.73 undefined
20090.06 undefined-2.95 undefined-2.31 undefined
20080.02 undefined-4.48 undefined-4.27 undefined
20070.05 undefined-5.42 undefined-4.77 undefined
20060.01 undefined-7.92 undefined-8.49 undefined
20050 undefined-9.03 undefined-8.68 undefined
20040 undefined-3.38 undefined-2.19 undefined

ReNeuron Group business model

The ReNeuron Group PLC is a British biopharmaceutical company specializing in the development of novel therapies for the treatment of neurological diseases such as stroke, Parkinson's, and spinal cord injuries. It was founded in 1997 and is headquartered in Guildford, Surrey. ReNeuron initially focused on researching stem cells, particularly neural stem cells, to use them for the regeneration of nerve tissue. This innovative method was intended to revolutionize the treatment of brain and spinal cord injuries. In 2006, the company successfully developed and conducted clinical trials on the first neural stem cell therapy candidate. However, the development of cellular therapies posed challenges, particularly in terms of product safety and efficacy. Therefore, ReNeuron adjusted its business strategy and has since been working on the development of exosomal products and bioproducts. Exosomes are small membrane vesicles secreted by cells. The proteins, nucleic acids, and lipids contained within them play a crucial role in cellular processes and could represent a new class of therapeutic agents. With these two new focuses, ReNeuron aims to continue being innovative and maintain its position as a leader in the biotech industry. The ReNeuron Group PLC is divided into three main areas: Core Business, NeuDiscovery, and Incubator. The Core Business is dedicated to the development and commercialization of novel therapeutic approaches for neurological diseases. The company works on the development of exosomal products, bioproducts, and cell-based therapies to aid in brain and spinal cord injuries. In developing these products, the company collaborates closely with leading research institutions, universities, and other biopharma companies. In NeuDiscovery, ReNeuron follows an "Open-Platform" strategy and provides external researchers with access to its exosomal drug library. The company expects this to lead to the discovery of new therapeutic approaches and the application of its own technology in other areas of medicine. Incubator is an internal initiative aimed at creating and supporting start-up biotech companies. The company offers its technology and expertise to this division and invests in promising projects. ReNeuron has also brought several significant products to the market in the past, including an experimental drug for the treatment of strokes based on neural stem cells. This therapeutic program has the potential to be a groundbreaking approach in stroke treatment, reducing the need for long-term medical interventions such as rehabilitation. Overall, ReNeuron is a strong force in the biotech industry and has the potential to revolutionize the face of medicine. The company has proven its ability to develop innovative and effective therapies while also adapting its business strategy to meet the regulations of the biopharmaceutical environment. ReNeuron Group is one of the most popular companies on Eulerpool.com.

ReNeuron Group SWOT Analysis

Strengths

1. Advanced stem cell therapy technology: ReNeuron Group PLC possesses cutting-edge stem cell therapy technology, which gives them a competitive advantage over other companies in the field.

2. Strong intellectual property (IP) portfolio: The company has a robust IP portfolio that provides them with legal protection and allows them to commercialize their therapies without significant competition.

3. Successful clinical trials: ReNeuron has a track record of successful clinical trials, demonstrating the effectiveness and safety of their therapies. This strengthens their credibility and increases investor confidence.

Weaknesses

1. Limited product portfolio: ReNeuron currently focuses on a narrow range of therapies, limiting their revenue streams and making them vulnerable to market fluctuations.

2. High research and development costs: The development and refinement of stem cell therapies require significant investments, which can put strain on ReNeuron's financial resources.

3. Regulatory uncertainties: The regulatory landscape surrounding stem cell therapies is evolving, and changes in regulations or approval processes may impact ReNeuron's ability to bring their products to market.

Opportunities

1. Growing market demand: The demand for regenerative medicine and innovative therapies is increasing globally, providing ReNeuron with opportunities to expand their customer base and generate more revenue.

2. Collaborations and partnerships: ReNeuron can explore strategic partnerships with pharmaceutical companies, research institutions, and healthcare organizations to accelerate product development, access new markets, and share resources.

3. Emerging markets: ReNeuron can target emerging markets where the adoption of stem cell therapies is still at a nascent stage, allowing for early market entry and potentially higher returns.

Threats

1. Intense competition: The field of stem cell therapy is highly competitive, with several established companies and new entrants vying for market share. ReNeuron faces the risk of losing customers to competitors.

2. Regulatory hurdles: Changes in regulations, particularly related to safety and efficacy requirements for stem cell therapies, could delay or prevent ReNeuron from obtaining necessary approvals or licenses.

3. Economic constraints: Economic downturns or budget cuts in healthcare spending can impact the financial stability of potential customers and limit their willingness to invest in advanced therapies, affecting ReNeuron's revenue.

ReNeuron Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ReNeuron Group historical P/E ratio, EBIT multiple, and P/S ratio

ReNeuron Group shares outstanding

The number of shares was ReNeuron Group in 2023 — This indicates how many shares 57.13 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ReNeuron Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ReNeuron Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ReNeuron Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ReNeuron Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ReNeuron Group stock splits

In ReNeuron Group's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for ReNeuron Group.

ReNeuron Group latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2021-0.13 -0.07  (47.78 %)2021 Q4
3/31/2020-0.21 -0.23  (-9.63 %)2020 Q4
9/30/2019-0.16 -0.12  (25.38 %)2020 Q2
3/31/2019-0.37 -0.28  (25.12 %)2019 Q4
1

ReNeuron Group shareholders

%
Name
Stocks
Change
Date
5.89039 % Octopus Investments Limited3,367,53420,2506/16/2023
5.65037 % Rosetta Capital Limited3,230,31810,7996/16/2023
5.27035 % Arix Capital Management Limited3,013,05713,0576/16/2023
3.73817 % Toscafund Asset Management LLP2,137,110470,0009/29/2023
1.40897 % Maven Capital Partners UK LLP805,50701/2/2024
1.22923 % Rahn+Bodmer Co.702,750200,0009/25/2023
1.07570 % Adams (Steven Paul)614,97509/25/2023
0.96204 % Ross (Iain)550,000150,0006/16/2023
0.87458 % Staehelin (Barbara)500,000150,0006/16/2023
0.69967 % Cockburn (Peter Nicholas)400,000304,0683/22/2023
1
2
3
4
5
...
10

ReNeuron Group Executives and Management Board

Mr. Iain Ross
ReNeuron Group Executive Chairman of the Board (since 2021)
Compensation 430,000
Mr. John Hawkins57
ReNeuron Group Chief Financial Officer, Director (since 2021)
Compensation 98,000
Ms. Barbara Staehelin60
ReNeuron Group Senior Independent Non-Executive Director
Compensation 60,000
Mr. Martin Walton60
ReNeuron Group Non-Executive Independent Director
Compensation 50,000
Dr. Michael Owen51
ReNeuron Group Non-Executive Independent Director
Compensation 48,000
1
2

ReNeuron Group Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Arix Bioscience Stock
Arix Bioscience
SupplierCustomer0,550,36-0,660,530,790,41
Shanghai Fosun Pharm H Stock
Shanghai Fosun Pharm H
SupplierCustomer0,230,010,280,360,670,31
Merck Stock
Merck
SupplierCustomer-0,390,28-0,160,830,27-0,34
1

Most common questions regarding ReNeuron Group

What values and corporate philosophy does ReNeuron Group represent?

ReNeuron Group PLC represents strong values and a corporate philosophy centered on innovation and excellence in the field of regenerative medicine. With an unwavering commitment to improving patients' lives, ReNeuron focuses on developing novel cell-based therapies to address critical medical needs. Their scientific expertise and state-of-the-art research facilities enable the company to advance groundbreaking treatments for conditions such as stroke and retinal diseases. ReNeuron Group PLC strives for ongoing collaboration with leading healthcare professionals and industry partners to deliver transformative therapies that have the potential to revolutionize the healthcare landscape.

In which countries and regions is ReNeuron Group primarily present?

ReNeuron Group PLC is primarily present in the United Kingdom.

What significant milestones has the company ReNeuron Group achieved?

ReNeuron Group PLC, a leading biotech company, has achieved several significant milestones. They have successfully developed and launched their innovative stem cell therapies, revolutionizing the field of regenerative medicine. The company has also conducted successful clinical trials, demonstrating the safety and efficacy of their treatments. ReNeuron has formed strategic partnerships with renowned academic institutions and pharmaceutical companies, further boosting their research and development capabilities. Additionally, they have received regulatory approvals for their therapies, paving the way for commercialization. ReNeuron Group PLC continues to make remarkable strides in unlocking the potential of stem cells for treating a range of debilitating diseases.

What is the history and background of the company ReNeuron Group?

ReNeuron Group PLC is a leading biotechnology company specializing in the development of cell-based therapies. Founded in 1997, ReNeuron has built a solid reputation for its groundbreaking research in stem cell technologies. The company focuses on developing treatments for various debilitating diseases, including stroke, retinitis pigmentosa, and critical limb ischemia. With its innovative therapies and committed research efforts, ReNeuron aims to provide effective, long-term solutions for patients in need. Over the years, ReNeuron Group PLC has garnered recognition for its scientific advancements and remains dedicated to advancing the field of regenerative medicine.

Who are the main competitors of ReNeuron Group in the market?

The main competitors of ReNeuron Group PLC in the market include companies such as StemCells Inc., Athersys Inc., and Mesoblast Limited.

In which industries is ReNeuron Group primarily active?

ReNeuron Group PLC is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of ReNeuron Group?

The business model of ReNeuron Group PLC is focused on developing and commercializing cell-based therapies for the treatment of diseases and injuries. The company specializes in stem cell research and uses its unique proprietary technologies to create advanced therapies for conditions like stroke, retinal diseases, and peripheral arterial disease. ReNeuron Group PLC aims to capitalize on the potential of cell-based treatments and is dedicated to advancing the field of regenerative medicine. By leveraging their expertise in stem cell science, the company strives to provide innovative solutions that address significant unmet medical needs and improve patient outcomes.

What is the P/E ratio of ReNeuron Group 2024?

The ReNeuron Group P/E ratio is 0.19.

What is the P/S ratio of ReNeuron Group 2024?

The ReNeuron Group P/S ratio is 0.03.

What is the Quality Investing of ReNeuron Group?

The Quality Investing for ReNeuron Group is 4/10.

What is the revenue of ReNeuron Group 2024?

The expected ReNeuron Group revenue is 660,540 GBP.

How high is the profit of ReNeuron Group 2024?

The expected ReNeuron Group profit is 103,935.06 GBP.

What is the business model of ReNeuron Group

The ReNeuron Group PLC is a biopharmaceutical company that focuses on the development of cell therapies for serious diseases. The business model of ReNeuron Group includes three different divisions: therapeutics, research, and services.

What is the ReNeuron Group dividend?

ReNeuron Group pays a dividend of 0 GBP distributed over payouts per year.

How often does ReNeuron Group pay dividends?

The dividend cannot currently be calculated for ReNeuron Group or the company does not pay out a dividend.

What is the ReNeuron Group ISIN?

The ISIN of ReNeuron Group is GB00BF5G6K95.

What is the ReNeuron Group WKN?

The WKN of ReNeuron Group is A2JBKZ.

What is the ReNeuron Group ticker?

The ticker of ReNeuron Group is RENE.L.

How much dividend does ReNeuron Group pay?

Over the past 12 months, ReNeuron Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ReNeuron Group is expected to pay a dividend of 0 GBP.

What is the dividend yield of ReNeuron Group?

The current dividend yield of ReNeuron Group is .

When does ReNeuron Group pay dividends?

ReNeuron Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ReNeuron Group?

ReNeuron Group paid dividends every year for the past 0 years.

What is the dividend of ReNeuron Group?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is ReNeuron Group located?

ReNeuron Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von ReNeuron Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ReNeuron Group from 10/19/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/19/2024.

When did ReNeuron Group pay the last dividend?

The last dividend was paid out on 10/19/2024.

What was the dividend of ReNeuron Group in the year 2023?

In the year 2023, ReNeuron Group distributed 0 GBP as dividends.

In which currency does ReNeuron Group pay out the dividend?

The dividends of ReNeuron Group are distributed in GBP.

All fundamentals about ReNeuron Group

Our stock analysis for ReNeuron Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ReNeuron Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.